142 related articles for article (PubMed ID: 38502366)
1. Safety and effectiveness of Janus kinase inhibitors in the management of inflammatory bowel disease following liver transplantation.
Con D; Hilley P; Chin S; Corte C; Hafeez B; Testro A; De Cruz P; Choy M; Srinivasan A
J Crohns Colitis; 2024 Mar; ():. PubMed ID: 38502366
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic Anticoagulation Is Associated With a Lower Risk of Recurrent Venous Thromboembolic Events During Janus Kinase Inhibitor Use for Patients With a Prior Thrombosis.
Lowell JA; Sharma G; Swaminath A; Sultan K
Inflamm Bowel Dis; 2024 May; ():. PubMed ID: 38704439
[TBL] [Abstract][Full Text] [Related]
3. Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.
Davies SC; Hussein IM; Nguyen TM; Parker CE; Khanna R; Jairath V
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012381. PubMed ID: 31984480
[TBL] [Abstract][Full Text] [Related]
4. Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases.
Núñez P; Quera R; Yarur AJ
Drugs; 2023 Mar; 83(4):299-314. PubMed ID: 36913180
[TBL] [Abstract][Full Text] [Related]
5. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.
Chimalakonda A; Burke J; Cheng L; Catlett I; Tagen M; Zhao Q; Patel A; Shen J; Girgis IG; Banerjee S; Throup J
Dermatol Ther (Heidelb); 2021 Oct; 11(5):1763-1776. PubMed ID: 34471993
[TBL] [Abstract][Full Text] [Related]
6. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
Olivera PA; Lasa JS; Bonovas S; Danese S; Peyrin-Biroulet L
Gastroenterology; 2020 May; 158(6):1554-1573.e12. PubMed ID: 31926171
[TBL] [Abstract][Full Text] [Related]
7. Janus Kinase Inhibitors for the Management of Patients With Inflammatory Bowel Disease.
Sedano R; Ma C; Jairath V; Feagan BG
Gastroenterol Hepatol (N Y); 2022 Jan; 18(1):14-27. PubMed ID: 35505771
[TBL] [Abstract][Full Text] [Related]
8. Are all JAK inhibitors for the treatment of rheumatoid arthritis equivalent? An adjusted indirect comparison of the efficacy of tofacitinib, baricitinib, upadacitinib, and filgotinib.
Vallez-Valero L; Gasó-Gago I; Marcos-Fendian Á; Garrido-Alejos G; Riera-Magallón A; Plaza Diaz A; Martinez-Molina C; Mangues-Bafalluy MA; Corominas H
Clin Rheumatol; 2023 Dec; 42(12):3225-3235. PubMed ID: 37831336
[TBL] [Abstract][Full Text] [Related]
9. JAK inhibitors: A new dawn for oral therapies in inflammatory bowel diseases.
Herrera-deGuise C; Serra-Ruiz X; Lastiri E; Borruel N
Front Med (Lausanne); 2023; 10():1089099. PubMed ID: 36936239
[TBL] [Abstract][Full Text] [Related]
10. Real-World Experience with Tofacitinib in IBD at a Tertiary Center.
Weisshof R; Aharoni Golan M; Sossenheimer PH; El Jurdi K; Ollech JE; Pekow J; Cohen RD; Sakuraba A; Dalal S; Rubin DT
Dig Dis Sci; 2019 Jul; 64(7):1945-1951. PubMed ID: 30734234
[TBL] [Abstract][Full Text] [Related]
11. Persistence of Janus-kinase (JAK) inhibitors in rheumatoid arthritis: Australia wide study.
Scheepers L; Yang Y; Chen YL; Jones G
Semin Arthritis Rheum; 2024 Feb; 64():152314. PubMed ID: 38029717
[TBL] [Abstract][Full Text] [Related]
12. Off-Label Use of Janus Kinase Inhibitors in Inflammatory Cutaneous Diseases.
Agarwal A; Diaz A; Al-Dehneem R; Pineda RM; Khattri S
J Drugs Dermatol; 2023 Dec; 22(12):1183-1190. PubMed ID: 38051858
[TBL] [Abstract][Full Text] [Related]
13. Relative efficacy and safety of Janus kinase inhibitors for the treatment of active psoriatic arthritis: a network meta-analysis.
Lee YH; Song GG
Z Rheumatol; 2023 Jun; 82(5):408-416. PubMed ID: 34716775
[TBL] [Abstract][Full Text] [Related]
14. ToRaRI (Tofacitinib in Rheumatoid Arthritis a Real-Life experience in Italy): Effectiveness, safety profile of tofacitinib and concordance between patient-reported outcomes and physician's global assessment of disease activity in a retrospective study in Central-Italy.
D'Alessandro F; Cazzato M; Laurino E; Morganti R; Bardelli M; Frediani B; Buongarzone C; Moroncini G; Guiducci S; Cometi L; Benucci M; Ligobbi F; Marotto D; Mosca M
Clin Rheumatol; 2024 Feb; 43(2):657-665. PubMed ID: 38135860
[TBL] [Abstract][Full Text] [Related]
15. Understanding the efficacy of individual Janus kinase inhibitors in the treatment of ulcerative colitis for future positioning in inflammatory bowel disease treatment.
Nakase H
Immunol Med; 2023 Sep; 46(3):121-130. PubMed ID: 37036140
[TBL] [Abstract][Full Text] [Related]
16. Janus kinase inhibitors for the treatment of COVID-19.
Kramer A; Prinz C; Fichtner F; Fischer AL; Thieme V; Grundeis F; Spagl M; Seeber C; Piechotta V; Metzendorf MI; Golinski M; Moerer O; Stephani C; Mikolajewska A; Kluge S; Stegemann M; Laudi S; Skoetz N
Cochrane Database Syst Rev; 2022 Jun; 6(6):CD015209. PubMed ID: 35695334
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Biologic Agents for the Management of Inflammatory Bowel Disease After Liver Transplantation.
Shaikh SA; Fitzgerald L; Tischer S
Pharmacotherapy; 2017 Dec; 37(12):1578-1585. PubMed ID: 28960437
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular risks associated with Janus kinase inhibitors: peering outside the black box.
Misra DP; Pande G; Agarwal V
Clin Rheumatol; 2023 Feb; 42(2):621-632. PubMed ID: 36264400
[TBL] [Abstract][Full Text] [Related]
19. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
Danese S; Vermeire S; Zhou W; Pangan AL; Siffledeen J; Greenbloom S; Hébuterne X; D'Haens G; Nakase H; Panés J; Higgins PDR; Juillerat P; Lindsay JO; Loftus EV; Sandborn WJ; Reinisch W; Chen MH; Sanchez Gonzalez Y; Huang B; Xie W; Liu J; Weinreich MA; Panaccione R
Lancet; 2022 Jun; 399(10341):2113-2128. PubMed ID: 35644166
[TBL] [Abstract][Full Text] [Related]
20. COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study.
Alexander JL; Liu Z; Muñoz Sandoval D; Reynolds C; Ibraheim H; Anandabaskaran S; Saifuddin A; Castro Seoane R; Anand N; Nice R; Bewshea C; D'Mello A; Constable L; Jones GR; Balarajah S; Fiorentino F; Sebastian S; Irving PM; Hicks LC; Williams HRT; Kent AJ; Linger R; Parkes M; Kok K; Patel KV; Teare JP; Altmann DM; Goodhand JR; Hart AL; Lees CW; Boyton RJ; Kennedy NA; Ahmad T; Powell N;
Lancet Gastroenterol Hepatol; 2022 Nov; 7(11):1005-1015. PubMed ID: 36088954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
